PERTH, Australia – Sydney-based Cochlear Ltd. reported its first loss in 25 years due to the COVID-19 pandemic and a patent battle loss in the U.S. For fiscal year 2020, which ended June 30, Cochlear reported a AU$238 million (US$170 million) loss in sales, down 186% from last year’s profit of AU$276 million.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: American Medical Technologies, Fitbit, Medtronic, Myriad Genetics, Nanodropper, Pear Therapeutics, Serve You Rx, Todos Medical.
Keeping you up to date on recent developments in neurology, including: Novasignal’s Lucid robotic system reveals insights into COVID-19; Sensing eye mask developed to improve data capture in neuro studies; Multiple sclerosis’ early days; How antidepressants inhibit fibrosis.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Auris, Genmab, Lung, Medicenna, Novartis, Silence, Sorrento, Technovax.
The U.S. FDA has granted emergency use authorization (EUA) to Lumiradx UK Ltd. for its point-of-care SARS-CoV-2 antigen test, which aims to speed the diagnosis of people suspected of having the virus that causes COVID-19. The test detects antigen nucleocapsid protein from a nasal swab taken from symptomatic patients and delivers results in less than 12 minutes.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Curetis, Lumiradx, Opgen, Pelvital, Zymo Research.
Keeping you up to date on recent developments in diagnostics, including: Antigen test detects spike proteins of SARS-CoV-2; Blood volume assessment study to use Daxor device; Gaining insights into loss of function.
RSS
